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Storage of canine packed red blood cells (pRBCs) can increase erythrocyte 
phosphatidylserine (PS) expression and eicosanoid concentrations.  The objective of this 
study was to determine the effects of leukoreduction on erythrocyte PS expression and 
eicosanoid concentrations in stored units of canine pRBCs.  Units of whole blood were 
leukoreduced (LR) or non-leukoreduced (non-LR), and stored (10 and 21 days) as 
pRBCs.  Samples were collected at donation, and before and after a simulated 
transfusion.  PS expression was measured by flow cytometry, and concentrations of 
arachidonic acid (AA), prostaglandin F2α (PGF2α), prostaglandin E2 (PGE2), prostaglandin 
D2 (PGD2), thromboxane B2 (TXB2), 6-keto-prostaglandin F1α (6-keto-PGF1α) and 
leukotriene B4 (LTB4) were quantified by liquid chromatography-mass spectrometry.  
Our study demonstrated that PS expression on the surface of erythrocytes was not 
affected by leukoreduction or storage duration.  Additionally, the passage of blood 
through a leukoreduction filter causes an immediate and dramatic increase in TXB2 and 
PGF2α concentrations, but these concentrations then decrease during subsequent storage.  
 
 
Despite leukoreduction, the concentration of 6-keto-PGF1α continued to increase during 
storage and simulated transfusion.  Overall, when compared to non-LR units, the addition 
of a leukoreduction step prior to storage had a minimal impact on the accumulation of 
eicosanoids in canine units of pRBCs. While leukoreduction may be beneficial in other 
aspects of transfusion medicine, based on the results in this study, using leukoreduction 
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CHAPTER I 69 
INTRODUCTION 70 
History of Transfusion Medicine 71 
Blood transfusions are commonly used for the treatment of life-threatening 72 
anemia in today’s critical veterinary patients.  Modern day blood transfusion techniques 73 
were developed not in a single day’s achievement, but rather through a long journey and 74 
contribution from many researchers.  In humans, blood transfusions have been used as 75 
life saving techniques for many, many years.  In contrast, although the first blood 76 
transfusion recorded was performed in a dog, veterinary transfusion medicine has 77 
somewhat lagged, only significantly developing over the past several decades.   78 
The first documented transfusion in any species occurred in 1665 when Richard Lower 79 
withdrew blood from one dog and replaced it with blood from another dog.  Over the 80 
next several decades, transfusing of blood from animals to humans was described but 81 
quickly outlawed due to the high rate of fatal reactions.1,2 It wasn’t until 1818, 150 years 82 
after the first recorded canine transfusion, when James Blundell, a British obstetrician, 83 
performed the first successful transfusion of human blood to a patient for the treatment of 84 
postpartum hemorrhage. Using the patient's husband as a donor, he extracted a small 85 
amount of blood from the husband's arm and, using a syringe, he successfully transfused  86 
the wife. During the 19th and 20th centuries, human transfusion medicine exploded with 87 
the development of sterile technique by Joseph Lister, the discovery of human blood  88 
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  89 
groups A, B and O by Karl Landsteiner, the establishment of anticoagulants, blood 90 
banking systems and the American Red Cross as well as the development of stringent 91 
blood storage and transfusion standards regulated by the Food and Drug Administration.2  92 
Although much blood transfusion research was originally performed with 93 
animals, veterinary transfusion medicine was not established until recently, most likely 94 
secondary to shifting views of animals as companions rather than property, and the desire 95 
for better animal health care.   Due to the increasing availability of equipment and 96 
facilities over the past several decades, transfusion of various blood products to 97 
companion animals has become a common practice in not only advanced care facilities, 98 
but general practices as well. As knowledge, has grown and the availability of different 99 
blood products has increased, however, transfusion therapy has become more complex.  100 
Blood from animal donors may be collected and immediately transfused, or 101 
collected and stored for use in patients at a later date.  Furthermore, blood can be 102 
separated into different components, including but not limited to, packed red blood cells, 103 
platelet concentrate, plasma and cryoprecipitate.3,4  Component products allow clinicians 104 
to tailor-make treatment plans most appropriate for the individual patient. To further 105 
increase the availability of blood products, storage of these products becomes necessary, 106 
and can result in significant changes within the unit.  These changes are known as 107 
“storage lesions” and can contribute to reactions and decreased survival of the transfused 108 
product within the recipient.5,6 Furthermore, several methods have been developed to 109 




  112 
intended to describe multiple aspects of veterinary transfusion medicine including 113 
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CHAPTER II 166 
REVIEW OF THE LITERATURE 167 
Transfusion Reactions 168 
With the increasing availability of canine and feline blood products, transfusion 169 
reactions are frequently encountered.  Consequently, significant strides have been made 170 
in the understanding of these reactions and how to limit their occurrence in our veterinary 171 
patients. The incidence of transfusion reactions may vary depending on several factors 172 
including storage time, storage techniques, underlying disease of the recipient, type of 173 
product transfused and amount of product transfused. Currently, transfusion reactions 174 
occur in 3-28% of canine and feline transfusions.1–6  175 
Transfusion reactions can be categorized into acute and delayed,  as well as 176 
immunologic and non-immunologic in origin.  Acute immunologic reactions include 177 
febrile non-hemolytic reactions, acute hemolysis, allergic/anaphylactic reactions and 178 
transfusion-related acute lung injury (TRALI).  The most common types of acute 179 
immunologic reactions include febrile non-hemolytic and allergic reactions however the 180 
most life-threatening reaction encountered is acute hemolysis.7–10  Delayed immunologic 181 
reactions may occur days to months following a transfusion.  Types of delayed 182 
immunologic reactions include hypersensitivity reactions II to IV which may manifest as 183 





 Immunologic reactions result from interactions between the recipients immune 187 
system and a variety of cells, compounds and inflammatory mediators within the blood 188 
product. Antibody-antigen interactions, especially directed against leukocytes and 189 
platelets within blood products, can result in an increase in systemic levels of cytokines 190 
and other pro-inflammatory mediators. Antibody binding to transfused mast cells and 191 
basophils can lead to degranulation and secretion of pro-inflammatory and vasoactive 192 
substances such as histamine, cytokines, and eicosanoids.  The ability of transfusions to 193 
modulate the recipient’s immune system is well established and characterized by the term 194 
transfusion-related immunomodulation (TRIM).7,11,12  Underlying physiologic 195 
mechanisms behind TRIM are multifactorial and determined not only by the 196 
immunogenic potential of the transfused product, but also by the recipients underlying 197 
disease process and genetic predisposition.  The benefits of transfusion-induced 198 
immunomodulation was first described in renal transplant recipients in which 199 
immunosuppressive effects resulted in higher success rates.13  Deleterious effects have 200 
since been described and are linked to manifestations such as viral activation, increased 201 
occurrence of postoperative infection and TRALI.11,14 Described mechanisms by which 202 
allogeneic transfusions may cause immunomodulation include depression of cellular 203 
immunity by downregulation of T-helper type 1 and upregulation of T-helper type 2 cells, 204 
dysregulation of innate immunity during inflammation by decreased natural killer cell 205 
and macrophage function as well as neutrophil priming and endothelial cell 206 
activation.11,15 The “two-insult” model of post-transfusion injury proposes that an initial 207 




  210 
condition or trauma primes the patient’s immune cells or endothelium, and further 211 
inflammation is triggered by a second immunomodulating insult (eg, transfusion), 212 
resulting in an unrestrained inflammatory response.  This theory maybe the underlying 213 
mechanism behind TRALI.14,16  Transfusion-related acute lung injury is the most 214 
common cause of transfusion-related deaths in human, however, despite the theoretical 215 
background for TRIM and TRALI, conclusive evidence of adverse clinical consequences 216 
of immunomodulation is lacking in veterinary patients and warrants further investigation. 217 
Regarding non-immunologic transfusion reactions, the most common include 218 
infectious disease transmission, sepsis from bacterial contamination of the unit, citrate 219 
toxicity leading to hypocalcemia (in patients receiving massive transfusions), and 220 
circulatory overload.9,17 Typically, clinical signs of a transfusion reaction manifest early 221 
in transfusion administration and may include fever, urticaria, facial edema, vomiting, 222 
weakness, tachycardia or bradycardia, tachypnea, dyspnea, hypotension, hypothermia and 223 
collapse.5,18  Signs consistent with a transfusion reaction can often be masked by the 224 
clinical signs associated with the underlying immune mediated disease.3,5,10,17,18  225 
With the expansion of veterinary transfusion medicine, standardized protocols 226 
regarding product processing and storage, donor and recipient testing, product 227 
administration and monitoring/treatment of reactions have been developed to best utilize 228 
blood products while avoid transfusion reactions.19,20  Processing of veterinary blood 229 
products primarily consists of sterile collection via a blood collection set into a storage 230 




  233 
components (such as fresh plasma, packed red blood cells, platelets concentration and 234 
cryoprecipitate) or stored as whole blood.  Each product may require a specific storage  235 
environment and storage time. For example, whole blood is stored in a refrigerator at 4C 236 
for a maximum of 35 days whereas fresh plasma may be frozen at -40C and stored for 1 237 
year.9 Proper storage of blood products decreases the risk of both immunologic and non- 238 
immunologic reactions. 239 
Careful selection of donor animals should be performed. Perhaps the most 240 
important criterion for donors is to meet minimum standards for infectious disease 241 
testing.  According to the most recent consensus statement regarding canine and feline 242 
blood donor screening for blood-borne pathogens, minimal standards for dogs should 243 
include a negative test result for Anaplasma platys and phagocytophilum PCR, Ehrlichia 244 
canis PCR or serology, Babesia canis vogeli and Babesia gibsoni PCR, Bartonella 245 
henselae and vinsonii subspecies berkhoffi PCR and Mycoplasma haemocanis PCR.  246 
Minimal standards for cats include negative testing for Anaplasma phagocytophilum PCR 247 
or serology, Bartonella henselae PCR, Mycoplasma haemofelis PCR, feline leukemia 248 
virus antigen testing and feline immunodeficiency virus antibody testing.  Infectious 249 
agents for which testing is recommended are chosen based on the agents documented 250 
ability to cause clinical infection in recipients after blood transmission, ability of the 251 
agent to cause subclinical infection such that carriers might inadvertently be identified as 252 
healthy blood donors, whether or not the agent can be detected using culture or molecular 253 




  256 
infection in the recipient has the potential to cause life-threatening illness and be difficult 257 
to eliminate with antimicrobial drugs.21  258 
Blood typing and cross matching are methods available to identify compatible 259 
blood products prior to administration, in an effort to avoid immunologic reactions.  260 
Canine blood types are characterized by the antigens present on the red blood cell.  While 261 
many canine antigens have been identified by sensitizing dogs with canine allogeneic 262 
blood, only dog erythrocyte antigens (DEA) 1.1, 1.2, 3, 4, 5 and 7 can be routinely 263 
measured.9  DEA 1.1 is highly antigenic and therefore can result in a severe hemolytic 264 
transfusion reaction if DEA 1.1 positive blood is administered to a sensitized DEA 1.1 265 
negative dog. Screening dogs for the presence or absence of this antigen is recommended 266 
prior to transfusion.8,9  DEA 1.1 typing is readily available as a point-of-care test and the 267 
Quick test DEA 1.1. The DEA 1.1 frequency of 42 to 71.2% varies with geographical 268 
location and breed.8  Recently, another erythrocyte antigen, the Dal antigen has been 269 
identified on canine red blood cells and can be absent in the Dalmation and Doberman 270 
breed.22  Furthermore, Kai 1 and Kai 2 are two recent blood types discovered by 271 
screening monoclonal antibodies.  Discovery of Kai is the first discovery of canine blood 272 
types by use of this technique.23 Feline blood types are determined by 3 alleles (A, ab and 273 
b) with A being dominant over the rare ab, which is dominant over b. Cats with a geno- 274 
type A/A, A/ab, or A/b are type A, whereas only cats with b/b are type B. Rare AB cats 275 
are genotypically ab/ab or ab/b.  Type A occurs in the majority (97%) of cats in the 276 
United States while type B occurs in 0.3-6% of cats with a predilection for exotic breeds 277 
such as the Devon rex (41%), British shorthair (36%), Cornish rex (31%), exotic  278 
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  279 
shorthair (27%), and Scottish fold (19%). Type AB appears to be rare and occurs in 280 
approximately 1% of the cat population worldwide.24 Recently, a feline blood antigen,  281 
termed Mik, has been identified and can play a role in blood incompatibility in cats that 282 
lack this antigen.25  283 
Cross matching enables identification of recipient antibodies to donor red blood 284 
cells (major cross match) as well donor antibodies to recipient red blood cells (minor 285 
cross match).  Point-of-care cross matching kits are available for rapid determination of 286 
blood compatibility.  Current recommendations are that all donors and recipients should 287 
be blood typed and cross matched prior to transfusion.8–10  In the canine species, an acute 288 
reaction is less likely to occur in a recipient receiving a transfusion for the first time.  289 
This is due to the lack of naturally-occurring alloantibodies against the majority of the 290 
DEA groups; specifically, DEA 1.1 alloantibodies have not been observed in the 291 
canine.26 Therefore, on an emergency basis only, forgoing typing and cross matching is a 292 
viable option for dogs that have not received a prior transfusion or have not been 293 
otherwise sensitized. In the cat, typing and ideally cross matching should always be 294 
performed prior to a transfusion due to the presence of naturally-occurring alloantibodies 295 
and high risk of a severe transfusion reaction in this species if incompatible blood is 296 
administered.8,9  For cats, point-of-care testing will identify A or B blood.  In summary, 297 
with the majority of cases, pre-transfusion typing and cross matching should be 298 
performed in order to provide the most compatible product for the recipient to limit the 299 
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Despite screening donors, providing adequate processing/storage methods and 303 
identifying blood compatibility via typing and cross matching, transfusion reactions still 304 
occur and are likely related to the presence and development of substances within the  305 
blood product itself that can result in stimulation of the recipient’s immune system. 306 
These immune-modulating substances include entire cells, cell particles, cytokines and 307 
lipid mediators.  They can be present at the time of collection of the blood product, such 308 
as leukocytes and platelets, or may develop/accumulate during storage secondary to 309 
altered metabolism, oxidative stress and accelerated product degradation.  The latter, 310 
termed storage lesions, are a subject of much research as they can be a significant 311 
contributor to product survival as well as immune responses in the recipient. 312 
Storage Lesions 313 
The occurrence of a transfusion reaction within the recipient is multifactorial 314 
however storage of blood products prior to administration has been associated with 315 
increased risk of reaction as well as morbidity and mortality in the recipient.1,27,28  In an 316 
effort to ensure adequate preservation of the units and safety to the recipient, standards of 317 
canine and feline blood storage have been established and are largely based on human 318 
protocols in which red blood cell products are stored for no longer than 42 days following 319 
the Food and Drug Administration requirement that 75% of transfused red cells must 320 
remain in circulation 24 hours after transfusion and hemolysis must affect less than 1% of 321 
stored cells at the end of the storage period.19,20,29 Regardless of these protocols, changes 322 
within the unit occur, and can be categorized into mechanical, biochemical and 323 
immunologic events.12   324 
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Mechanical events include alterations secondary to physical manipulation of the 326 
product including transient changes in ambient temperature, kinking of tubing, clogging 327 
of filters, centrifugation or rough handling that results in shearing or lysis of cells,  328 
damage to cellular membranes, decreased deformability of erythrocytes, increased 329 
phosphatidylserine expression and microparticle formation.  Mechanical events may 330 
occur at any time, however most likely occur with increased incidence during handling 331 
such as in collection of the product, product filtration or transfusion to the recipient. 332 
Biochemical events occur during storage, and result from the artificial 333 
environment in which the contents of the product are maintained.   This artificial 334 
environment results in altered metabolism and oxidative stress. Biochemical changes 335 
include decreased adenosine triphosphate (ATP), 2,3 diphosphoglycerate (DPG) and 336 
nitric oxide (NO), as well as increased potassium leakage, ammonia accumulation and 337 
oxidative injury. 338 
Because mammalian red blood cells do not contain mitochondria, they depend on 339 
anaerobic glycolysis to produce two ATP and two lactic acid molecules per one glucose 340 
molecule.  An important enzyme in this pathway is phosphofructokinase which is 341 
inhibited by the progressingly acidic environment in storage.  As a result, ATP 342 
production falls and results in membrane instability as well as failure of many 343 
intracellular processes such as phosphorylation of membrane phospholipids and proteins, 344 
membrane transport functions, synthesis of purine and pyrimidine nucleotides, and 345 
synthesis of glutathione.12,30 Hemoglobin and 2,3 DPG bind resulting in reduced affinity 346 
of hemoglobin for oxygen in erythrocytes, and allowing effective release of oxygen to  347 
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peripheral tissues.30 It is produced from a side pathway of anaerobic glycolysis and as a 349 
result of decreased metabolism, 2,3DPG decreases in storage.  Importantly however, 350 
decreased 2,3 DPG has not been shown to affect oxygen delivery to the tissues when  351 
transfused to rats.31 Nitric oxide is an uncharged radical produced by the vascular 352 
endothelium and is a major endogenous vasodilator. Within red blood cells, NO binds to 353 
a residue of hemoglobin to form S-nitrosohemoglobin (SNO-Hb). During storage, 354 
erythrocyte SNO-Hb bioactivity falls rapidly and is not restored following infusion into a 355 
recipient.  It has been suggested that this may impair tissue oxygen delivery after RBC 356 
transfusions.12,32 Oxidative reactions occur during normal metabolism and produce 357 
reactive oxygen and nitrogen species.  Naturally, these products are reduced and result in 358 
minimal cellular injury.  Mechanism to avoid oxidative injury depend largely on cellular 359 
glutathione levels.30  In storage, decreased metabolism and ATP results in depleted 360 
glutathione and progressive cellular injury and destruction.12,32  Through altered 361 
metabolism, oxidative stress and cellular injury, levels of free hemoglobin, potassium and 362 
ammonia increase in product supernatant.12  Free hemoglobin secondary to hemolysis and 363 
hemoglobin-containing microparticles can react with NO after transfusion to form 364 
methemoglobin and nitrate.33 The consequences of increased potassium and ammonia in 365 
the supernatant of veterinary blood products is of uncertain significance and additional 366 
research in this area is required. 367 
Immunologic changes that occur in units during storage primarily result from 368 
interaction with the white blood cell population.34 Leukocytes in packed red blood cell 369 
units can become activated, producing and releasing pro-inflammatory cytokines such as  370 
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interleukin-8.35,36  Additionally leukocytes lyse early in storage and release enzymes that 372 
not only result in damage to the erythrocyte but also contribute a portion of pro- 373 
inflammatory and pro-thrombotic compounds including elastase, secretory 374 
phospholipase-A2, soluble FAS-ligand, prostaglandin E-2 and transforming growth 375 
factor-1.37,38  376 
Phosphatidylserine 377 
An increase in phosphatidylserine (PS) expression on the red cell surface is a well 378 
described red cell storage lesion of human blood products that results from 379 
damage/degradation of the erythrocyte.39–41 Phosphatidylserine is a negatively charged 380 
phospholipid, comprising a portion of the erythrocyte cell membrane.  The majority of 381 
cell membranes in the eukaryote, including the erythrocyte cell membrane, are comprised 382 
of a lipid bilayer with neutral phospholipids (phosphatidylcholine and sphingomyelin)  on 383 
the outer leaflet of the cell membrane and negatively charged phospholipids 384 
(phosphatidylserine, phosphatidylinositol and phosphatidylethanolamine) on the inner 385 
surface.42  386 
In circulation, as the erythrocyte ages or becomes damaged, alterations occur to 387 
the cell membrane that allow for immune recognition and removal of the cell from 388 
circulation via phagocytosis. One change of interest is PS translocating to the outer cell 389 
membrane layer. At rest, PS is located within the inner leaflet of the plasma membrane, 390 
but with aged or damaged erythrocytes, PS expression will gradually translocate to the 391 
cell surface which will signal the need for cell removal via mononuclear phagocytic 392 
cells.42 Consequently, in storage, the expression of PS on the surface of the red blood cell  393 
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serves as an indicator for erythrocyte health.43 Other changes that occur in the 395 
aged/damaged erythrocyte includes an increase in senescent antigen formation, IgG 396 
binding, loss of cell adhesion molecules, vesicle formation and loss of cell pliability.44,45  397 
On average, a canine erythrocyte’s life span in circulation is 120 days, however, 398 
in storage, erythrocyte degradation occurs at a faster rate. Phosphatidylserine expression 399 
on the erythrocyte surface can be correlated to the availability of ATP.  ATP allows 400 
function of the enzyme aminophospholipid translocase which actively flips PS back to 401 
the inner surface of the cells.  Lack of ATP results in inadequate aminophospholipid 402 
translocase activity and increased PS expression.46  403 
During storage, erythrocytes are primed for ATP depletion and intracellular 404 
potassium leakage which enhances PS expression on the erythrocyte surface.39 405 
Furthermore, increased PS expression in units of packed red cells may promote 406 
procoagulant activity.  In other cell types, PS expression is involved in angiogenesis, 407 
thrombin formation, and the regulation of vascular tone and can serve as a marker for 408 
potential inflammatory and procoagulant activity.40,41,47 Phosphatidylserine-expressing 409 
platelets in circulation play a pivotal role in activating the coagulation cascade.48   410 
Phosphatidylserine-expressing erythrocytes do not appear to cause a similar effect, 411 
possibly in part because senescent erythrocytes are cleared quickly from the circulation.40 412 
In stored blood products, however, the amount of PS expression can accumulate and 413 
potentially shorten the circulating survival time of the transfused erythrocyte, or 414 
contribute to transfusion-related complications. In human research, Lu et al demonstrated 415 
that increased erythrocyte PS expression in red blood cell concentrate is associated with  416 
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increased procoagulant activity, and that both the amount of PS expression and 418 
procoagulant activity increased with the length of storage.41 Furthermore, leukoreduction 419 
(removal of white blood cells and platelets) of whole blood prior to storage can decrease 420 
this procoagulant activity.40,49,50 421 
Several techniques have been developed to identify PS-expressing cells including 422 
the use of chemical reagents or phospholipases to alter the externalized phospholipids, 423 
techniques to monitor the redistribution of added phospholipid probe molecules across 424 
the cell membrane, and the activation of hemostatic processes such as PS-mediated 425 
activation of prothrombin to thrombin via prothrombinase.51,52 426 
  Flow cytometry is a technique available to identify and sort cell populations.  427 
Using flow cytometry, PS-expressing erythrocytes can be identified and quantified by 428 
using fluorescently labeled annexin V.  Annexins are a family of proteins that bind to 429 
charged phospholipids particularly PS.  Fluorescently labeled annexins have been used to 430 
identify PS on the surface of activated platelets under physiologic conditions in vitro as 431 
well as on the surface of vesicles released from activated platelets and apoptotic cells.51,53  432 
Radioactively labeled annexin V has been used to identify PS exposure in red cells.53  433 
However, binding of radiolabeled annexin V only indicates the loss of phospholipid 434 
asymmetry in the average cell and does not allow analysis of the erythrocyte population. 435 
Kuypers et al. described the technique in human red blood cells showing that 436 
fluorescently labeled annexin V used in conjunction with flow cytometry and fluorescent 437 
microscopy offers an excellent method for the determination of loss of normal 438 
phospholipid asymmetry in subpopulations or individual red cells.46   439 
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Eicosanoids 441 
Eicosanoids are signaling molecules primarily derived from arachidonic acid. 442 
Eicosanoids include the prostaglandins, leukotrienes and lipoxins and are involved in a 443 
wide range of physiologic processes including the regulation of inflammation, vascular 444 
and bronchial tone, platelet aggregation, uterine and gastrointestinal motility, and renal 445 
blood flow as well as hypothalamic/pituitary hormone secretion.54 Eicosanoids play an 446 
important role in modifying physiological processes in both homeostatic and 447 
inflammatory condition via their interaction with signaling molecules such as cytokines 448 
and chemokines.54 Furthermore, eicosanoids can modify inflammatory responses 449 
depending on the type and location of the receptor to which they bind. Specifically, 450 
thromboxane promotes platelet aggregation, vasoconstriction and bronchoconstriction.55  451 
Thromboxane can also enhance the production of interleukin-8, a pro-inflammatory 452 
cytokine and potent neutrophil chemoattractant55,56 Cys leukotrienes, those containing a 453 
cysteine residue, specifically leukotriene B4, recruit neutrophils and other cells of 454 
inflammation to site of tissue damage. Other leukotrienes (specifically, leukotriene D4) 455 
trigger contractions in the smooth muscles lining the bronchioles and act in asthma and 456 
allergic disease. Prostaglandin F2α (PGF2α) can regulate the cytokine response of mast 457 
cells, while PGI2 is known to modulate immune cell functions, specifically T helper 458 
cells.57,58 Lipoxins, which were the first eicosanoids to be identified and recognized as 459 
potential anti-inflammatory mediators, are able to inhibit the production of IL-12 by 460 




  463 
Eicosanoids are synthesized from a wide range of cells including leukocytes, vascular 464 
epithelial cells, and platelets.  Although erythrocytes contain arachidonic acid  (AA), they 465 
do not possess the oxidative enzymes required for AA metabolism.60
 
Biosynthesis of 466 
eicosanoids depends on the availability of AA which is produced from membrane 467 
phospholipids by the action of phospholipase A2. Arachidonic acid can be metabolized 468 
through three main pathways: the cyclooxygenase (COX) pathway producing the 469 
prostanoids; the lipoxygenase (LO) pathway producing the leukotrienes and lipoxins and 470 
the P-450 epoxygenase pathway producing hydroeicosatetraenoic acids (HETEs) and 471 
epoxides.54  The pattern of eicosanoid production is determined in a stimulus and cell- 472 
specific fashion. All cell membranes of the eukaryote contain a rich source of 473 
phospholipids and AA, however some cells, the erythrocyte for example, lack COX and 474 
LO and therefore are incapable of production of most eicosanoids.  475 
Transcellular biosynthesis is described as the cooperation of cells to produce 476 
eicosanoids: one cell type is activated to synthesize an intermediate compound, through a 477 
primary oxidative enzyme (COX or LO), that is transferred to a neighboring cell to carry 478 
out the final synthesis.  The second cell does not need to be activated, but can convert the 479 
intermediate compound to the biologically active form by the presence of secondary 480 
enzymes such as prostaglandin isomerases, LTA4 hydrolase or LTC4 synthase. For 481 
example, LTA4 produced by neutrophils can be converted into LTC4 by vascular 482 
epithelium or into LTB4 by erythrocytes.  Also, PGI2 is produced from platelet derived 483 
PGH2 by vascular epithelium or lymphocytes.




  486 
Multiple analytical techniques for quantitation of eicosanoids have been 487 
developed and include immunoassays such as enzyme-linked immunosorbent assay 488 
(ELISA) or radio-immunoassays (RIA), and gas chromatography (GC) or liquid 489 
chromatography (LC) coupled to mass spectrometry (MS) or tandem mass spectrometry 490 
(MS-MS).61–63 Immunoassays provide excellent sensitivity but can only be used for the 491 
quantification of single analytes, and are susceptible to cross-reactions. These 492 
impairments are overcome by GC-MS or GC-MS-MS, but these methodologies are labor 493 
intense and time consuming due to the requirement of derivatization prior to analysis.  494 
LC-MS-MS based methods have become highly valuable in the measurement of various 495 
eicosanoids and other chemicals in biological samples because of their high sensitivity, 496 
high selectivity and simplicity of sample preparation.64–67  497 
While there is little information in human literature and even less in veterinary 498 
literature regarding eicosanoids and stored blood products, some reports have 499 
documented that certain eicosanoids and other lipids accumulate with prolonged storage.
 
500 
In a previous study, our research group has demonstrated a significant increase in an 501 
array of eicosanoids during storage and transfusion of canine packed red blood cells.68 502 
Similarly, Jacobi et al demonstrated that prostaglandin E2 (PGE2) and thromboxane B2 503 
(TXB2) increased during storage, but stated these levels remained within physiologic 504 
limits and likely do not contribute to the risk of immunomodulated transfusion 505 
reactions.69
 
Spinelli et al, demonstrated that PGE2 and TXB2 levels increased with 506 
storage, and that leukoreduction prior to storage significantly decreased TXB2 507 
accumulation and, to a lesser degree, PGE2 as well.
70 Since leukocytes and platelets are  508 
 
20 
  509 
primarily responsible for the production of eicosanoids within stored blood products, it is 510 
reasonable to assume that leukoreduction may serve to decrease eicosanoid accumulation. 511 
Recently however, other human reports have linked accumulation of biologically active  512 
lipids, including arachidonic acid, in stored whole blood with transfusion-related acute 513 
lung injury (TRALI) even in units that have been leukoreduced.15
 
 514 
Transfusion-related acute lung injury has been linked to a number of mediators 515 
including biologically active lipids. Silliman et al, provide evidence that bioactive lipids 516 
that accumulate during storage may contribute to TRALI as a result of neutrophil 517 
priming. Lipids identified in that study included nonpolar lipids such as arachidonic acid, 518 
HETE, 12-HETE and 15-HETE. These lipids accumulate in red blood cell concentrates 519 
and therefore it is presumed they can be produced from peroxidation in addition to 520 
enzymatic conversion from arachidonic acid.15  Lysophosphatidylcholine (lyso-PC) is 521 
another lipid derived from phospholipid membranes that can accumulate in storage and 522 
prime neutrophils.  Both the non-polar lipids and lyso-PCs accumulate despite removing 523 
the platelet and leukocyte population and therefore the risk of TRALI is not completely 524 
diminished by the process of leukoreduction.16,71  Although no veterinary studies have 525 
evaluated lipids and their role in transfusion reactions, it is reasonable to believe these 526 
lipids can accumulate in companion animal blood products as well.  Further studies are 527 
needed to identify these lipids as well as to evaluate whether storage conditions can affect 528 





  532 
Efforts to Reduce Storage Lesions 533 
Storage lesions can be minimized by specific processing procedures either before 534 
storage or immediately prior to transfusion to the recipient.  These procedures include 535 
leukoreduction prior to or after storage, post-storage cell washing, and rejuvenation prior 536 
to administration.12 With leukoreduction prior to storage, the majority of leukocytes and 537 
platelets are extracted from the unit of blood via passage through a specialized filter, 538 
preventing these cells from influencing the environment within the unit and reducing the 539 
inflammatory response associated with blood transfusion in the recipient.27 Pre-storage 540 
leukoreduction has been shown in veterinary medicine to effectively remove 99% of 541 
donor leukocytes.72 Despite this, leukoreduction is not commonly performed in veterinary 542 
clinics.  This is most likely due to decreased availability and a lack of knowledge 543 
regarding whether leukoreduction is beneficial in companion animals. In units of stored 544 
human packed red blood cells, the removal of leukocytes and platelets via specialized 545 
leukoreduction filters prior to storage results in a significant reduction in PS expression 546 
on erythrocytes.40
 
In veterinary medicine, Herring et al, determined that PS expression on 547 
microparticles can be identified in canine whole blood, and that leukoreduction will 548 
attenuate the expression of PS on microparticles.73
 
However, in that study, because 549 
microparticle PS expression was measured, it is unclear from which cell line PS 550 
originated. Currently, it is unknown how leukoreduction and storage will affect the 551 
expression of PS directly on the canine red blood cell. While leukoreduction removes the 552 
leukocyte and platelet population, it can still leave behind microparticles, free 553 
hemoglobin and inflammatory mediators.  Additionally, levels of thromboxane B2 can  554 
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  555 
increase during the leukoreduction process, which may be relevant when blood products 556 
are leukoreduced post-storage and immediately administered to the recipient.74  This 557 
technique is no longer recommended in humans due to subsequent hypotension.75 558 
Alternatively, post-storage washing of RBCs prior to transfusion may help remove 559 
products left behind from leukoreduction. During the washing process, saline is added to 560 
erythrocyte units then the units are centrifuged and the supernatant is removed.  Several 561 
human studies have proven the benefit of washing units prior to transfusion including a 562 
reduction in inflammatory markers.76–80 Additional research is needed in veterinary 563 
medicine to assess the potential benefit of post-storage washing. Rejuvenation is another 564 
post-storage method developed to address storage lesions. During rejuvenation, a solution 565 
containing inosine, phosphate, and adenine is added to stored erythrocyte units prior to 566 
transfusion to restore RBC morphology, ATP, and 2,3 DPG concentrations. Rejuvenation 567 
appears to be beneficial in human research, however studies are lacking in companion 568 
animals.81,82 Overall, strategies to minimize storage lesions have proven beneficial in 569 
human medicine.  This may translate similarly to veterinary medicine however cost 570 
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  928 
CHAPTER III 929 
Effect of leukoreduction and storage on erythrocyte phosphatidylserine expression and 930 
eicosanoid concentrations in units of canine packed red blood cells.  931 
Introduction 932 
Blood transfusions are commonly used for the treatment of anemia in critical 933 
veterinary patients. Storage of blood products, although necessary, creates an unnatural 934 
environment that can lead to accelerated product degradation.1
 
In humans and dogs, a 935 
direct correlation has been established between blood product storage time and increased 936 
morbidity and mortality in transfused patients, suggesting that stored blood products can 937 
undergo significant changes that lead to an increased risk of complications in the 938 
recipient.2-7 Numerous studies have investigated red blood cell storage lesions, and 939 
several mechanisms have been identified as contributors to the degradation of stored 940 
erythrocytes.1,4,8    941 
In humans, an increase in phosphatidylserine (PS) expression on the red cell surface 942 
is one recognized storage lesion.9-11 Phosphatidylserine is a negatively charged 943 
phospholipid, comprising a portion of the erythrocyte cell membrane.  Normally, PS is 944 
confined to the inner leaflet of the erythrocyte cell membrane but, in aged or damaged  945 
erythrocytes, PS will translocate to the cell surface and serve as an indicator of 946 
erythrocyte quality.  An increase in expression of erythrocyte PS will signal the need for 947 
cell removal via mononuclear phagocytic cells, potentially decreasing the life span of 948 




  951 
Recently, it has been demonstrated that there is a significant accumulation of 952 
eicosanoids, such as prostaglandin F2α (PGF2α), leukotriene B4 (LTB4), thromboxane B2 953 
(TXB2), and 6-keto-prostaglandin F1α (6-keto-PGF1α, a stable prostacyclin metabolite), in 954 
units of canine packed red blood cells (pRBCs) during storage and transfusion.15  955 
Eicosanoids are signaling molecules derived from arachidonic acid.  These molecules are 956 
involved in a wide range of physiologic processes that include maintenance of vascular 957 
and bronchial tone, platelet aggregation, gastrointestinal motility, and renal blood flow. 958 
Additionally, eicosanoids can modulate the inflammatory response via the interaction 959 
with signaling molecules, cytokines and chemokines,16 potentially contributing to the 960 
development of transfusion reactions.  Although it is unknown how eicosanoids within 961 
blood products will affect the recipient during a transfusion, the infusion of prostacyclin 962 
in dogs has been shown to cause immediate and dramatic vasodilation.17 Additionally, 963 
other eicosanoids within blood products, such as thromboxane, which causes platelet 964 
activation and vasoconstriction, could adversely affect the transfusion recipient. 965 
Eicosanoids are synthesized from a wide range of cells, including leukocytes, 966 
vascular epithelial cells and platelets. Although erythrocytes contain arachidonic acid, 967 
they do not possess the oxidative enzymes involved in arachidonic acid metabolism and  968 
eicosanoid synthesis.18 The leukocyte and platelet populations inside units of pRBCs are 969 
probably the major contributors to arachidonic acid metabolism.15  In humans, leukocytes 970 





  974 
increase in PS expression, and contribute to the synthesis of proinflammatory molecules, 975 
including phospholipaseA2, which can contribute to eicosanoid production.
4,19  With the 976 
use a leukoreduction filter prior to storage, the majority of leukocytes and platelets are 977 
extracted from the unit of blood, preventing these cells from influencing the environment 978 
inside the pRBC unit, and reducing the inflammatory response associated with 979 
transfusions.20 In units of stored human pRBCs, the removal of leukocytes and platelets 980 
via leukoreduction prior to storage causes a significant reduction in erythrocyte PS 981 
expression.10  Reduction in concentrations of leukocytes and platelets within the unit also 982 
removes the main source of eicosanoid synthesis.   983 
Currently, it is unknown how leukoreduction and storage will affect erythrocyte 984 
PS expression and eicosanoid concentrations in units of canine pRBCs.  The objective of 985 
this study was to determine the effects of leukoreduction on erythrocyte PS expression 986 
and eicosanoids that accumulate in units of canine pRBCs after storage and transfusion.  987 
Our hypothesis was that the use of a leukoreduction filter to eliminate the majority of 988 
leukocytes and platelets from pRBCs prior to storage would significantly decrease 989 
erythrocyte PS expression and eicosanoid concentrations.   990 
Materials and Methods 991 
Animals 992 
Dogs were chosen from our research colony and included in the study if they were 993 
determined to have normal health status and they were not exposed to any medications or 994 
vaccines for at least 2 weeks prior to initiation of the study. Normal health status was 995 
established by detection of no abnormalities on physical examination, complete blood  996 
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count, serum chemistry, urinalysis, and heartworm and tick-borne disease testing. Animal 998 
use was approved by the Mississippi State University Institutional Animal Care and Use 999 
Committee and was in compliance with the requirements of a facility accredited by the 1000 
American Association for Accreditation of Laboratory Animal Care.  1001 
Blood Donation, Leukoreduction, and Sample Collection  1002 
The donors were randomly separated into one of two groups, a leukoreduction 1003 
(LR) group and a non-leukoreduction (non-LR) group.  Each dog underwent a standard 1004 
blood donation.  Briefly, the donors were positioned in either right or left lateral 1005 
recumbency, and the fur overlying the jugular vein was clipped and the skin aseptically 1006 
prepared.  A 16-gauge needle was inserted into the jugular vein and approximately 450 1007 
milliliters of blood was collected aseptically, under negative pressure, into a standard 1008 
triple blood banking baga for the non-LR group and a quadruple blood banking bagb, 1009 
containing a leukoreduction filter, for the LR group. The units contained an anticoagulant 1010 
citrate phosphate dextrose solution.  There were no adverse events detected in the donor 1011 
dogs during or after blood collection.   1012 
For the LR group, the unit was leukoreduced and platelet-depleted by passage of 1013 
blood through a leukoreduction filter directly after collection.  To assess the extent of 1014 
leukoreduction, blood samples were collected before and after leukoreduction from the 1015 
in-line tubing system for a total leukocyte and platelet count using an automated 1016 
hematologic analyzer.c For both LR and non-LR groups, pRBCs were created by 1017 
separating the red cells and plasma via centrifugation.  To remove the plasma following 1018 
centrifugation, external pressure was applied to the blood bag, and the plasma was passed  1019 
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via a connecting tube into an attached empty bag for subsequent storage as fresh frozen 1021 
plasma.  While still containing plasma, the connecting tube between the two blood bags 1022 
was sealed and removed.  The plasma in the sealed tube was collected, snap frozen in 1023 
liquid nitrogen, and stored at -80oC. This plasma represented the initial sample 1024 
(“donation sample”) for eicosanoid analysis.  The remaining unit of pRBC was 1025 
separated, to create two half units, by applying external pressure to the unit and allowing 1026 
erythrocytes to pass, via a connecting tube, into an attached empty bag.  While still 1027 
containing red blood cells, the connecting tube between the two blood bags was sealed 1028 
and used as the initial sample (“donation sample”) for PS expression. Each half unit of 1029 
pRBCs was stored vertically at 4oC in a dedicated refrigerator for 10 or 21 days.  The 1030 
donors underwent at least a 28-day recovery period after blood collection, switched 1031 
groups and the process was repeated. 1032 
On Day 10 of storage, one half unit from each dog (4 LR and 4 non-LR) was 1033 
removed and samples were collected for analysis.  When removed from refrigeration, 1034 
each half unit was infused with 50 mL of 0.9% saline, mixed gently, and 1 mL of 1035 
reconstituted packed red blood cells was removed from the unit for measure of PS 1036 
expression.  An additional 20 mL of reconstituted packed red blood cells were collected, 1037 
centrifuged, and the supernatant was removed for eicosanoid analysis.  This sample was 1038 
snap frozen in liquid nitrogen and stored at -80oC until analysis.  The collected 1039 
erythrocytes and supernatant represented the “Day 10 pre-transfusion” samples.  To 1040 
mimic transfusion conditions, the remainder of each half unit was left at room 1041 
temperature for 5 hours. At the completion of this time period, using the same procedures  1042 
 
36 
  1043 
as mentioned above, a 1 mL sample was collected and processed for the measurement of 1044 
erythrocyte PS expression, and a 20 mL sample was collected for eicosanoid analysis. 1045 
The collected erythrocytes and supernatant represented the “Day 10 post-transfusion” 1046 
samples.   On Day 21 of storage, the 8 half units of pRBCs that had remained in 1047 
refrigeration were removed and processed similar to the Day 10 samples.  The 1048 
erythrocytes and supernatant collected on Day 21 of storage represented the “Day 21 pre- 1049 
transfusion” and “Day 21 post-transfusion” samples. 1050 
Phosphatidylserine Analysis  1051 
A flow cytometric assay was used to quantitate the expression of PS on canine 1052 
erythrocytes.  Labeling of cells was performed based on a previously described 1053 
protocol.21 Personnel performing flow cytometry were blinded to knowledge of whether 1054 
samples were LR or non-LR. For red blood cell preparation, 50 µL of concentrated 1055 
erythrocytes were washed twice with FACS-PBS, containing 0.2% bovine serum 1056 
albumind, and 10 µL of the washed red blood cells were resuspended in 90 µL of FACS- 1057 
PBS.  For flow cytometric analysis, 16 µL of washed RBCs were incubated with 1058 
annexin-V-FITCe and annexin binding buffer for 15 minutes in the dark at room 1059 
temperature.  After incubation, 400 µL of annexin binding buffer was added, gently 1060 
mixed, and analyzed within one hour.  Flow cytometric analysis was performed with a 1061 
flow cytometerf and computer software.g  Red blood cell populations were displayed on 1062 
log forward-scatter versus log side-angle light scatter plots. Gates were adjusted to 1063 
baseline erythrocyte populations, and 5,000 gated events were recorded for each labeling.  1064 
For quality control, both positive and negative controls were included. Expression was  1065 
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quantified by the intensity of annexin-V-FITC fluorescence and expressed as median 1067 
fluorescence intensity (MFI).    1068 
Eicosanoid Analysis  1069 
Using a previously established technique,22 the concentrations of arachidonic acid (AA), 1070 
prostaglandin E2 (PGE2), prostaglandin D2 (PGD2), PGF2α, TXB2 (a stable metabolite of  1071 
thromboxane A2), 6-keto-PGF1α (a stable, hydrolyzed product of prostacyclin (PGI2)) and 1072 
LTB4 were analyzed by liquid chromatography-mass spectrometry. Personnel performing 1073 
spectrometry were blinded to knowledge of whether samples were LR or non-LR. The 1074 
thawed plasma/saline supernatant, which contained deuterated internal standards (d4-8- 1075 
iso PGF2α, d4-LTB4, and d8-arachidonic acid), were extracted by using C18 SepPak 1076 
columns.h After drying, 10 μl of the resolubilized lipids was injected onto an Acquity 1077 
UPLC BEH C18 column (1.7 µm, 100 ×2.1mm I.D.).i The analytes were eluted from the 1078 
analytical column with a gradient program and directed into a mass spectrometer.j  The 1079 
concentrations were determined by measuring the area under the chromatographic peak 1080 
and comparing this value to the area under the chromatographic peak for the internal 1081 
standard. A computer software programk was employed for data acquisition and 1082 
processing.  The eicosanoid concentrations were normalized to the volume of plasma 1083 
used for analysis and expressed as pmol/ml plasma.  The estimated limits of detection 1084 
with this protocol are between 0.1-10 nM on-column. 1085 
Statistical Analysis 1086 
Sample size calculation was performed based on previously published data.15  The 1087 
assumptions used in the calculations were an alpha of 0.05 and a power of 0.95.  An  1088 
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estimated sample size of 8 dogs would detect if the concentrations of 6-keto-PGF1α and 1090 
TXB2 following leukoreduction would be similar to the initial donation sample.  A linear 1091 
mixed model was fit with PROC MIXED in a statistical software programl for the each 1092 
outcome.  Run, sequence, filter, sample, and the filter and sample interaction were 1093 
included as fixed effects with a Kenward-Rogers degrees of freedom method specified. 1094 
Dog identity was included as random effect with a variance component covariance 1095 
structure specified.  Repeated measures of dog identity within run for the different 1096 
samples were specified in a repeated statement with a spatial power law covariance 1097 
structure.  The interaction term was dropped from the model if it was not significant.  If 1098 
the interaction term was significant, differences in least squares means between each of 1099 
the concentrations of one variable were calculated for each concentration of the other 1100 
variable in the interaction using an LSMESTIMATE statement.  The simulate adjustment 1101 
for multiple comparisons was used for significant effects.  The distribution of the 1102 
conditional residuals was evaluated for each outcome to ensure the assumptions of the 1103 
statistical model had been met.  An alpha level of 0.05 was used to determine statistical 1104 
significance for all methods. 1105 
Results 1106 
Animals 1107 
 Eight healthy adult research Walker Hound dogs, five males and three females, 1108 
were used in this study.  The mean age of the dogs was 1.5 years (range, 1.5 to 6.5 years), 1109 




  1112 
Leukoreduction 1113 
The leukocyte and platelet counts prior to and after leukoreduction are 1114 
represented in Figure 1.  Leukoreduction was effective at removing all leukocytes, 1115 
however, although leukoreduction was effective at removing 98.3% of the platelets in 7 1116 
of the 8 units, but there was only a partial reduction in platelet count (59.7%) in one unit. 1117 
Phosphatidylserine Expression 1118 
The MFI of erythrocyte PS expression is summarized in Table 1.  Compared to 1119 
the respective donation sample, there was no significant changes in the MFI at any time 1120 
point for the non-LR units and the LR units.  Additionally, when comparing the MFI 1121 
between the non-LR and LR units, there were no significant differences at any time 1122 
points.    1123 
Eicosanoid Concentration 1124 
The eicosanoid concentrations for the non-LR and LR units at all time points are 1125 
represented in Table 2. There was no difference in AA, PGE2, PGD2, and LTB4 1126 
concentrations at any time point, nor was there a difference in the concentrations between 1127 
non-LR and LR units.  1128 
At the time of donation, the PGF2α concentrations in LR units were significantly 1129 
(p<0.0001) greater than non-LR units.  PGF2α concentrations in LR units then dropped 1130 
rapidly with storage, such that there was no difference in PGF2α concentration between 1131 
the LR and non-LR units for any of the remaining time points.  For the LR-units, the 1132 
PGF2α concentration in all of the subsequent samples, pre and post transfusion, were 1133 
significantly (p<0.01) less than the initial donation sample.  There was no significant  1134 
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difference in PGF2α concentration among the pre and post transfusion samples collected 1136 
from the LR units on Days 10 and 21.  There was no difference in PGF2α concentration 1137 
among the samples collected from the non-LR units. 1138 
At the time of donation, the TXB2 concentrations in LR units were significantly 1139 
(p<0.0001) greater than non-LR units.  TXB2 concentrations in LR units then dropped 1140 
rapidly with storage, such that there was no difference in TXB2 concentration between 1141 
the LR and non-LR units for any of the remaining time points.  The TXB2 concentration 1142 
in all LR samples, except for Day 10 post-transfusion, was significantly (p<0.05) 1143 
decreased compared to the donation sample.  There was no significant difference in TXB2 1144 
concentration among the pre and post transfusion samples collected from the LR units on 1145 
Days 10 and 21.  There was no difference in TXB2 concentration among the samples 1146 
collected from the non-LR units. 1147 
When compared to the initial donation sample, there was a significant (p<0.0001) 1148 
increase in 6-keto-PGF1α concentrations irrespective of unit type for both LR and non-LR 1149 
units on both Days 10 and 21 for both the pre and post transfusion samples.  The day 10 1150 
post transfusion sample concentrations were significantly greater (p=0.0029) than the day 1151 
21 pre transfusion samples, irrespective of unit type.  The 6-keto-PGF1α concentrations 1152 
for the LR units were significantly increased (p=0.0163) compared to the non-LR unit 1153 
concentrations, irrespective of sample time.    1154 
Discussion 1155 
Transfusion with stored blood products has been associated with an increase in 1156 
morbidity and mortality in transfused patients, compared to transfusion with fresh  1157 
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products.2-8  In human medicine, increased PS expression on the red blood cell surface 1159 
and the accumulation of eicosanoids inside the stored unit are proposed mechanisms that 1160 
contribute to the degradation of stored erythrocytes and transfusion reactions.9-11, 23 With 1161 
the use a leukoreduction filter prior to storage, removing the majority of the leukocytes 1162 
and platelets from the unit, the environment inside the unit is thought to be less conducive 1163 
for the formation of storage lesions, which is proposed to reduce the inflammatory 1164 
response and reactions associated with transfusions.20 The results of our study 1165 
demonstrate that, in units of canine pRBCs, leukoreduction and storage have minimal 1166 
impact of erythrocyte PS expression, but alter concentrations of some eicosanoids.   1167 
Based on our study, erythrocyte PS expression was not altered by leukoreduction, 1168 
length of storage, or simulated transfusion.  Similar findings have been reported in human 1169 
studies, in which only a small percentage of PS-positive erythrocytes (3.5 to 4.5%) were 1170 
detected after prolonged storage times of up to 7 weeks using similar techniques.11,24-26 1171 
One possible explanation for why an increase in RBC PS expression was not detected is 1172 
that the PS positive portions of the erythrocyte membrane were released from the cell and 1173 
became microparticles in the unit.  In stored units of human pRBCs, erythrocytes can 1174 
undergo vesiculation to return to a PS-negative state by shedding PS-containing 1175 
vesicles.9,27  It is unknown when stored erythrocytes maximally express PS, but PS 1176 
expression probably occurs continuously, followed by vesicle formation.  In a previous 1177 
study evaluating units of canine RBC concentrates, PS expression on the surface of 1178 
microparticles increased during storage.28  Therefore, if the PS-positive microparticles in 1179 
units of canine pRBCs were released from erythrocytes, then the PS expression on  1180 
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individual red blood cells would have minimal change during leukoreduction, storage and 1182 
transfusion.   1183 
In humans, Burger et al demonstrated an increased erythrocyte PS expression 1184 
during storage of blood products, but this expression was transient and associated with 1185 
increasing amounts of PS-positive vesicle formation.  Additionally, the LR units were 1186 
stored for 42 days, twice as long as our study, and the PS expression only changed after 1187 
an overnight incubation at 37oC, to mimic the environment of red blood cells following a 1188 
transfusion.9  In our study, the units were subjected to 5 hours at room temperature 1189 
(approximately 21oC) to simulate the temperature change during a transfusion before the 1190 
erythrocytes enter the recipient, but we did not evaluate PS expression on erythrocytes at 1191 
a temperature that would mimic the body temperature of the recipient. It is possible that 1192 
with a longer storage time and greater erythrocyte incubation temperature, to mimic the 1193 
environment of transfused erythrocyte, we could have detected a change in PS expression 1194 
on RBCs.  Although PS translocation is a well-described storage lesion in humans,9-11 1195 
due to unpredictable vesiculation and the difficulty in determining microparticle origin, 1196 
using PS expression as a marker for erythrocyte quality in units of canine pRBCs can be 1197 
unpredictable and difficult to interpret.   1198 
In a previous study performed in dogs, storage of units of pRBCs caused a 1199 
decrease in arachidonic acid concentration, followed by a progressive increase in the 1200 
concentration of eicosanoids inside the units.15  One possible explanation for these 1201 
changes in eicosanoids during storage was a decline of cell health, particularly in 1202 
leukocytes and platelets, leading to a decrease in cell viability and an increase in  1203 
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enzymatic conversion of arachidonic acid to the various eicosanoids.  In humans, the pre- 1205 
storage removal of leukocytes and platelets via leukoreduction decreases the 1206 
concentrations of PGE2 and TXB2 in stored units of pRBCs.
29  In contrast, in our study, 1207 
the removal of leukocytes and platelets prior to storage did not significantly decrease 1208 
eicosanoid concentrations..  At most sample time points in our study, eicosanoid 1209 
concentrations were similar between LR and non-LR units, suggesting that 1210 
leukoreduction may have minimal impact on the accumulation of eicosanoids in units of 1211 
canine pRBCs.   1212 
Compared to non-leukoreduced units, the passing of blood through the 1213 
leukoreduction filter prior to storage created an immediate and marked increase in TXB2 1214 
and PGF2α concentrations. The increase in TXB2 concentration is particularly concerning 1215 
because, as a potent platelet activator and vasoconstrictor, an increase in this eicosanoid 1216 
could have a significant impact on the hemodynamic stability of transfusion recipients.  1217 
This concern, however, may only be applicable to blood products that are leukoreduced 1218 
and immediately administered to the recipient because, during storage, TXB2 1219 
concentrations in LR units decreased to concentrations similar to non-LR units.  It is 1220 
unknown for how long after leukoreduction TXB2 concentrations remain elevated but, 1221 
after 10 days of storage, the concentrations are similar to non-LR units.   1222 
A possible explanation for the increase in TXB2 concentration immediately 1223 
following leukoreduction is that platelets are activated as they adhere to the fibers within 1224 
the filter.  In human blood products, based on platelet shape change and pseudopod 1225 
formation, platelets appear to become activated as they pass through leukoreduction  1226 
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filters.30  Once activated, platelets will increase expression of integrins needed for 1228 
aggregation, change shape to cover a greater surface area, empty the contents of granules, 1229 
and release arachidonic acid to be converted to thromboxane A2.
31  After synthesis, 1230 
thromboxane A2 exhibits a very short half-life and is non-enzymatically decomposed to 1231 
the stable metabolite TXB2.
32  While platelets are the primary source of thromboxane A2, 1232 
several other cells are capable of synthesizing this eicosanoid, including leukocytes and 1233 
endothelial cells.32,33  Even though the cyclooxygenase (COX)-2 enzyme has been 1234 
identified in canine platelets,34  COX-1 is the primary isoform in platelets, and probably 1235 
responsible for the increased synthesis of TXB2 in units of pRBCs.  It is unknown how 1236 
elevated concentrations of TXB2 affect the patient, but the increased TXB2 associated 1237 
with leukoreduction and immediate transfusion may have the potential to adversely 1238 
impact the recipient.   1239 
In addition to TXB2, PGF2α also significantly increased immediately after 1240 
leukoreduction.  Prostaglandin F2α, is synthesized via three pathways from PGE2, PGD2, 1241 
or PGH2 by PGE 9-ketoreductase, PGD 11-ketoreductase, or PGH 9-,11-endoperoxide 1242 
reductase, respectively.35  Collectively referred to as prostaglandin F synthases (PGFS), 1243 
these enzymes are expressed in numerous organs including the liver, lung, brain, kidneys 1244 
and uterus, but PGFS mRNA has also been identified in peripheral blood lymphocytes.36  1245 
The mechanism of increased PGF2α after leukoreduction in this study is unclear, but it is 1246 
possible that PGFS were released from lymphocytes activated during the filtration 1247 
process.  Some studies have described leukocyte activation with the use of leukocyte 1248 
depletion filters,37-39 however, these findings were not consistently replicated in other  1249 
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leukoreduction studies.40-43  Furthermore, leukocyte rupture is possible with prolonged 1251 
filtration, resulting in free enzymes and other cellular components.44  Similar to TXB2, 1252 
the increase in PGF2α concentration following leukoreduction is particularly concerning 1253 
because PGF2α is associated with vasoconstriction and bronchoconstriction, which could 1254 
impact the hemodynamic stability of transfusion recipients.16 1255 
The decrease in TXB2 and PGF2α concentrations during storage could be 1256 
associated with the short half-life of these molecules.  Prostanoid activity is usually short 1257 
lived, and catabolism of these molecules occurs rapidly and primarily through the 1258 
pulmonary circulation.  Prostanoid catabolism involves several enzymes, particularly 15- 1259 
hydroxyprostaglandin dehydrogenase (15-PGDH), which results in oxidation of the 15- 1260 
OH group to the corresponding ketone.27,45,46 In addition to being found in high 1261 
concentrations in the lungs, 15-PGDH is located throughout the body, including a high 1262 
expression in leukocytes.47  Despite removal of the leukocyte population, the release of 1263 
15-PGDH from activated leukocytes at the time of leukoreduction may have contributed 1264 
to TXB2 and PGF2α catabolism.  1265 
Compared to our previous study,15 despite some similar trends, overall the 1266 
eicosanoid concentrations in this current study were significantly lower.  One potential 1267 
explanations for these differences include quantity of cells within the unit.  Unlike the 1268 
previous study which used greyhounds as donor dogs, our study used hound dogs which, 1269 
compared to greyhounds, have a lower percentage of circulating erythrocytes.  The 1270 




  1273 
in our previous study was 68%. The lower percentage of cells inside the units could have 1274 
contributed to this decrease in eicosanoid synthesis.   1275 
Biosynthesis of eicosanoids depends on the availability of arachidonic acid, which 1276 
is derived from membrane phospholipids by several enzymes, including phospholipase 1277 
A2. Once released, arachidonic acid can be metabolized by three main pathways: the 1278 
COX pathway that produces prostanoids, the lipoxygenase (LOX) pathway that produces 1279 
leukotrienes and lipoxins, and the P-450 epoxygenase pathway that produces epoxides.16 1280 
The erythrocyte membrane is a rich source of arachidonic acid, but lacks both the COX 1281 
and LOX enzymes, and therefore cannot produce the majority of eicosanoids.18 However, 1282 
the arachidonic acid-rich erythrocytes can contribute to eicosanoid synthesis via 1283 
transcellular biosynthesis, the cooperation among different cell types to produce 1284 
eicosanoids.  During transcellular biosynthesis, one cell type can synthesize an 1285 
intermediate compound, through a primary oxidative enzyme, which is transferred to a 1286 
neighboring cell to complete the final synthesis.  1287 
In our study, the only eicosanoid that increased in concentration during storage or 1288 
simulated transfusion was 6-keto-PGF1α. This was similar to a previous study that 1289 
identified an increase in 6-keto-PGF1α concentration in units of canine pRBCs during 1290 
storage and transfusion.15 This prostaglandin is produced via non-enzymatic conversion 1291 
from PGI2, which is derived by the vascular epithelium or lymphocytes.
16  Interestingly, 1292 
after the removal of the leukocytes and platelet via leukoreduction, the predominate cell 1293 
type expected to be remaining in the unit is the erythrocyte, which is not capable of 1294 
synthesizing prostanoids. Therefore, we presume that, despite leukoreduction,  1295 
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components within units of pRBCs contributed to increased concentrations of 6-keto- 1297 
PGF1α via a process similar to transcellular biosynthesis.  Specifically, arachidonic acid 1298 
could be derived from the rich phospholipid bilayer of erythrocytes, and converted to 1299 
prostacyclin via the COX-2 enzymes found in other cellular components within units of 1300 
pRBCs. 1301 
While it is unknown how the accumulation of eicosanoids in units of pRBCs will 1302 
affect physiologic responses within the transfusion recipient, considering the functions of 1303 
these molecules, the administration of blood products with elevated concentrations of 1304 
eicosanoids could have detrimental effects.  For example, thromboxane promotes platelet 1305 
aggregation, vasoconstriction and bronchoconstriction, all of which may adversely affect 1306 
hypercoagulable and hypertensive patients.16  Thromboxane can also enhance the 1307 
production of IL-8, a pro-inflammatory cytokine and potent neutrophil 1308 
chemoattractant48,49 and, therefore, may promote transfusion-associated inflammatory 1309 
responses. Additionally, transfusing blood products with high concentrations of 1310 
prostacyclin, which inhibits platelet aggregation and promotes vasodilation,16 may further 1311 
exacerbate complications associated with systemic hypotension in critical patients. 1312 
Although our study did not detect significant accumulation of eicosanoids, further studies 1313 
under a range of different storage conditions are needed to determine if eicosanoids can 1314 
accumulate in storage to a concentration significant enough to cause adverse effects in 1315 
the recipient.  1316 
 To determine the effectiveness of leukoreduction, leukocyte and platelet counts 1317 
were performed immediately before and after leukoreduction.  The filter was effective at  1318 
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removing all leukocytes, but the filters were less effective at removing platelets prior to 1320 
storage.  Seven units had a post-filter platelet count of less than 20 K/µL, but one unit had 1321 
137 K/µL platelets post filtration, a 60% reduction in platelet count compared to the pre- 1322 
filtration sample.  This elevated platelet count in the LR units could have altered the 1323 
results of our study.  If the eicosanoid and phosphatidylserine results from this unit were 1324 
removed from our analyses, however, there was no major change in overall results, and 1325 
the results from this unit were therefore included in our final analyses.     1326 
There were several limitations with this study.  One limitation was not using a 1327 
transfusion administration set during the simulated transfusion.  With the use of a 1328 
transfusion administration set and the passing of blood through an additional in-line 1329 
administration filter, additional changes could have developed in either eicosanoid 1330 
concentrations or PS expression.  Another limitation of this study was the storage length 1331 
of 21 days.  Compared to other studies investigating storage lesions, a 21-day storage 1332 
period may have been too short of time to detect a change in eicosanoid concentration or 1333 
PS expression, and it is possible that a longer storage duration would be associated with 1334 
greater changes.  Additionally, our study evaluated the prostanoids derived from the COX 1335 
pathway and LTB4 produced by the LOX pathway, but the epoxides synthesized by the 1336 
P-450 pathway were not measured.  Even though leukoreduction did not significant 1337 
reduce the eicosanoids measured in this study, it is possible that the removal of 1338 
leukocytes and platelets prior to storage could have reduced vasoactive epoxides.  1339 




  1342 
power for this study, including more dogs in this study may have provided additional 1343 
results.   1344 
Our study demonstrated that PS expression on the surface of erythrocytes was not 1345 
affected by leukoreduction or storage duration.  Additionally, the passage of blood 1346 
through a leukoreduction filter causes an immediate and dramatic increase in TXB2 and 1347 
PGF2α concentrations, but these concentrations then decrease during subsequent storage.  1348 
Despite leukoreduction, the concentration of 6-keto-PGF1α continued to increase during 1349 
storage and simulated transfusion.  Overall, when compared to non-LR units, the addition 1350 
of a leukoreduction step prior to storage had a minimal impact on the accumulation of 1351 
eicosanoids in canine units of pRBCs. While leukoreduction may be beneficial in other 1352 
aspects of transfusion medicine, based on the results in this study, using leukoreduction 1353 
to decrease PS expression and eicosanoid concentrations does not appear to be effective.   1354 
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Footnotes 1356 
a. Teruflex Optisol Triple Collection Blood Bag, Terumo Corporation, Tokyo, Japan  1357 
b. Imuflex-WB-RP Blood Bag with integral whole blood leukocyte reduction filter, 1358 
Terumo Corporation, Tokyo, Japan 1359 
c. Abbott Cell-Dyn® 3700, Abbott Laboratories, Abbott Park, IL 1360 
d. Bovine Serum Albumin, Sigma-Aldrich, St. Louis, MO 1361 
e. FITC Annexin V/Dead Cell Apoptosis Kit, Life Technologies, Grand Island, NY 1362 
f. FACSCalibur, BD Biosciences, San Jose, CA 1363 
g. CellQuest Pro software, BD Biosciences, San Jose, CA 1364 
h. HyperSep Retain PEP 60 mg, 1mL, Thermo Fisher Scientific, Waltham, MA 1365 
i. Acquity UPLC BEH C18 column, Waters Corporation, Milford, MA 1366 
j. TSQ Quantum Access Max, Thermo Fisher Scientific Inc, San Jose, CA  1367 
k. Xcaliber software, ThermoFisher Scientific Inc, San Jose, CA 1368 
l. SAS for Windows version 9.4, SAS Institute, Inc., Cary, NC 1369 
  1370 
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  1545 
Figure 3.1     Leukocyte (A) and platelet (B) counts prior to and after 1546 
leukoreduction.  LR, Leukoreduced 1547 
  1548 
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  1549 
Table 3.1    Based on flow cytometric analysis, the MFI (mean ± standard deviation) of 1550 
canine erythrocyte PS expression, with and without leukoreduction, at collection 1551 
(donation) and after various lengths of storage (pre-transfusion) and after a simulated 1552 
transfusion (post-transfusion).   1553 
Sample Non-LR Units of pRBCs LR Units of pRBCs 
Day 0 - Donation 7.74±1.04 7.57±0.83 
Day 10 – Pre-transfusion 7.28±1.10 7.21±0.68 
Day 10 – Post transfusion 7.13±0.93 6.99±1.25 
Day 21 – Pre transfusion 7.88±0.93 7.85±0.98 
Day 21 – Post transfusion 7.42±1.59 7.77±1.28 
 1554 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this study, units of packed red blood cells were evaluated for changes in both 
phosphatidylserine expression and eicosanoid concentrations in response to 
leukoreduction and various storage times.  The results of our study demonstrate that, in 
units of canine pRBCs, leukoreduction and storage have minimal impact on erythrocyte 
PS expression, but alter concentrations of some eicosanoids. Data obtained from this 
study have resulted in new ideas regarding future directions for research surrounding 
storage lesions. 
Significant changes in PS expression on erythrocytes were not noted in this study.  
As previously mentioned, similar findings have been reported in human studies, in which 
only a small percentage of PS-positive erythrocytes (3.5 to 4.5%) were detected after 
prolonged storage times of up to 7 weeks using similar techniques.1-4 One possible 
explanation for why an increase in RBC PS expression was not detected is that the PS 
positive portions of the erythrocyte membrane were released from the cell, becoming PS 
expressing microparticles in the unit.  In stored units of human pRBCs, erythrocytes can 
undergo vesiculation to return to a PS-negative state by shedding PS-containing 
vesicles.5,6  It is unknown when stored canine erythrocytes maximally express PS, but PS 
expression may occur continuously, followed by vesicle formation.  In a previous study 




microparticles increased during storage.7  Therefore, if the PS-positive microparticles in 
units of canine pRBCs were released from erythrocytes, then the PS expression on 
individual red blood cells would have minimal change during leukoreduction, storage and 
transfusion.  Future studies investigating both erythrocyte and microparticle PS 
expression concurrently in units of canine packed red blood cells would be helpful in 
clarifying this process.  
In humans, Burger et al demonstrated an increased erythrocyte PS expression 
during storage of blood products, but this expression was transient and associated with 
increasing amounts of PS-positive vesicle formation.  Additionally, the leukoreduced 
units were stored for 42 days, twice as long as our study, and the PS expression only 
changed after an overnight incubation at 37oC, to mimic the environment of red blood 
cells following a transfusion.5  In our study, the units were subjected to 5 hours at room 
temperature (approximately 21oC) to simulate the temperature change during a 
transfusion before the erythrocytes enter the recipient, but we did not evaluate PS 
expression on erythrocytes at a temperature that would mimic the body temperature of 
the recipient. Future studies that incorporate a longer storage time and greater erythrocyte 
incubation temperature, to mimic the environment of transfused erythrocyte, are needed 
to potentially detect a change in PS expression on RBCs.  Although PS translocation is a 
well-described storage lesion in humans,1,5,8 due to unpredictable vesiculation and the 
difficulty in determining microparticle origin, using PS expression as a marker for 
erythrocyte quality in units of canine pRBCs can be unpredictable and difficult to 




In humans, the pre-storage removal of leukocytes and platelets via leukoreduction 
decreases the concentrations of PGE2 and TXB2 in stored units of pRBCs.
9  In contrast, in 
our study, the removal of leukocytes and platelets prior to storage did not significantly 
decrease eicosanoid concentrations.  Alternatively, we observed a marked increase, 
specifically in TXB2, immediately post-leukoreduction, which raises concern regarding 
hemodynamic effects in the recipient.  Furthermore, storage resulted in an increase in 6-
keto-PGF1α, a stable prostacyclin metabolite. Transfusing blood products with high 
concentrations of prostacyclin, which inhibits platelet aggregation and promotes 
vasodilation, may further exacerbate complications associated with systemic hypotension 
in critical patients. However, it is unknown if the metabolites of thromboxane and 
prostacyclin are representative of the biologically active compound. Futhermore, it is 
unknown if these metabolites would have an effect on the recipient if transfused in high 
concentrations. Further studies under a range of different storage conditions are needed to 
determine if eicosanoids can accumulate in storage to a concentration significant enough 
to cause adverse effects in the recipient.  
The exploration of the clinical significance of storage lesions in veterinary 
medicine is quite limited. Large observational studies of human patients, especially those 
with trauma, after cardiac surgery, or in a pediatric intensive care unit, found associations 
between transfusions of older PRBCs and increased rates of sepsis, multiple organ 
dysfunction syndrome, mortality or some combination of these.10-12 Such studies raise 
concerns regarding whether older pRBC units should be used in critically ill patient 




association of pRBC storage duration on morbidity and mortality, the age of transfused 
pRBCs did not contribute to mortality in the general canine population, although there 
may be associations with multiple organ dysfunction and coagulopathies.13 Additionally, 
administration of older stored autologous RBCs has been shown to induce an 
inflammatory response in healthy dogs.14  
In this study, we identified changes in canine pRBC units in response to 
leukoreduction and storage, however, we do not know if these changes would 
significantly affect patients to which these units were transfused.  The next step in our 
research should involve prospective investigation of the recipient to which stored 
leukoreduced and non-leukoreduced allogenic units transfused.  Subsequent monitoring 
of the recipient along with analysis of blood samples for various procoagulant and 
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